Waters 将来の成長

NYSE:WAT - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	3,301	760	743	922	14
12/31/2025	3,112	712	762	914	18
12/31/2024	2,943	630	647	769	17
9/28/2024	2,905	623	620	752	N/A
6/29/2024	2,877	596	561	705	N/A
3/30/2024	2,909	604	514	669	N/A
12/31/2023	2,956	642	442	603	N/A
9/30/2023	2,995	653	390	571	N/A
7/1/2023	2,992	675	387	572	N/A
4/1/2023	2,966	689	425	610	N/A
12/31/2022	2,972	708	428	612	N/A
10/1/2022	2,950	697	465	631	N/A
7/2/2022	2,901	702	477	641	N/A
4/2/2022	2,868	705	565	727	N/A
12/31/2021	2,786	693	579	747	N/A
10/2/2021	2,736	695	626	797	N/A
7/3/2021	2,671	660	642	802	N/A
4/3/2021	2,509	616	697	857	N/A
12/31/2020	2,365	522	618	791	N/A
9/26/2020	2,295	504	536	715	N/A
6/27/2020	2,278	515	495	691	N/A
3/28/2020	2,358	537	430	619	N/A
12/31/2019	2,407	592	479	643	N/A
9/28/2019	2,405	577	491	633	N/A
6/29/2019	2,406	580	475	631	N/A
3/30/2019	2,403	591	467	604	N/A
12/31/2018	2,420	594	508	604	N/A
9/29/2018	2,392	55	489	615	N/A
6/30/2018	2,380	51	N/A	623	N/A
3/31/2018	2,342	27	N/A	699	N/A
12/31/2017	2,309	20	N/A	698	N/A
9/30/2017	2,251	548	N/A	679	N/A
7/1/2017	2,212	537	N/A	674	N/A
4/1/2017	2,190	533	N/A	656	N/A
12/31/2016	2,167	522	N/A	643	N/A
10/1/2016	2,125	498	N/A	623	N/A
7/2/2016	2,099	490	N/A	613	N/A
4/2/2016	2,057	467	N/A	567	N/A
12/31/2015	2,042	469	N/A	573	N/A
10/3/2015	2,040	469	N/A	568	N/A
7/4/2015	2,032	467	N/A	557	N/A
4/4/2015	2,019	457	N/A	550	N/A
12/31/2014	1,989	432	N/A	512	N/A
9/27/2014	1,971	422	N/A	493	N/A
6/28/2014	1,935	406	N/A	470	N/A
3/29/2014	1,904	399	N/A	473	N/A
12/31/2013	1,904	450	N/A	485	N/A

アナリストによる今後の成長予測

収入対貯蓄率: WATの予測収益成長率 (年間8.6% ) は貯蓄率 ( 2.6% ) を上回っています。

収益対市場: WATの収益 ( 8.6% ) US市場 ( 15.4% ) よりも低い成長が予測されています。

高成長収益: WATの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: WATの収益 ( 5.5% ) US市場 ( 9% ) よりも低い成長が予測されています。

高い収益成長: WATの収益 ( 5.5% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: WATの自己資本利益率は、3年後には高くなると予測されています ( 32.2 %)

Waters 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Price target increased by 7.5% to US$375

Waters Corporation Raises Earnings Guidance for the Full Year of Fiscal Year Ending December 31, 2024

Waters Corporation Provides Earnings Guidance for the Second Quarter and Full Year of 2024

Waters Corporation (NYSE:WAT) Released Earnings Last Week And Analysts Lifted Their Price Target To US$323

Price target increased by 7.8% to US$323

Waters Corporation Provides Earnings Guidance for the First Quarter and Full-Year 2024

Recent updates

Is Waters (NYSE:WAT) A Risky Investment?

Waters Corp: Short Reinvestment Runway Diminishes High Multiples

Price target increased by 7.5% to US$375

Second quarter 2024 earnings released: EPS: US$2.41 (vs US$2.56 in 2Q 2023)

Waters Corporation Raises Earnings Guidance for the Full Year of Fiscal Year Ending December 31, 2024

Now 20% undervalued

Waters Corporation Announces New Bioseparations Tools Accelerate and Improve Development of Rna-Based Vaccines and Therapies Using LC-MS Analysis

Waters Corporation Introduces TA Instruments Discovery Core Rheometer

Now 20% undervalued

Waters Corporation's (NYSE:WAT) Price Is Out Of Tune With Earnings

A Look At The Fair Value Of Waters Corporation (NYSE:WAT)

Waters Corp.: Embedded Expectations High Under Present Conditions

Does Waters (NYSE:WAT) Have A Healthy Balance Sheet?

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Waters Corporation to Report Q2, 2024 Results on Jul 31, 2024

Waters Corporation New Rapid Screening-DSC Enables Up to 24x Faster Thermal Stability Testing at Ultra-Low Sample Volumes for Antibody Drugs

Should You Think About Buying Waters Corporation (NYSE:WAT) Now?

Now 20% undervalued after recent price drop

Waters Corporation's (NYSE:WAT) Business Is Yet to Catch Up With Its Share Price

Waters Corporation: Still Struggling A Bit

Independent Director notifies of intention to sell stock

Waters Corporation Provides Earnings Guidance for the Second Quarter and Full Year of 2024

First quarter 2024 earnings: EPS misses analyst expectations

Estimating The Intrinsic Value Of Waters Corporation (NYSE:WAT)

Waters Corporation Accelerates the Development of Gene-Based Therapeutics with New GTxResolve Premier SEC Columns

Is It Too Late To Consider Buying Waters Corporation (NYSE:WAT)?

Waters Corporation, Annual General Meeting, May 23, 2024

We Think Waters (NYSE:WAT) Can Stay On Top Of Its Debt

Waters Corporation: A Great (Share Price) Run

Waters Corporation (NYSE:WAT) Released Earnings Last Week And Analysts Lifted Their Price Target To US$323

Price target increased by 7.8% to US$323

Waters Corporation Provides Earnings Guidance for the First Quarter and Full-Year 2024

Waters Corporation's (NYSE:WAT) Price Is Out Of Tune With Earnings

Waters Corporation: High Quality Niche Company In Mass Spectrometry

A Look At The Fair Value Of Waters Corporation (NYSE:WAT)

Is There Now An Opportunity In Waters Corporation (NYSE:WAT)?

Waters Corporation: Appealing Levels Are Offset By Weaker Performance

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Now 22% undervalued after recent price drop

Waters (NYSE:WAT) Seems To Use Debt Quite Sensibly

Waters Corporation Announces Resignation of Jonathan Pratt as Senior Vice President of the Waters Division

Waters Corporation Launched OligoWorks SPE Workflow and Kits

Waters Corporation: Buybacks Ceased, Incremental Returns Languishing (Rating Downgrade)

Waters Corporation Introduces DynaPro™? ZetaStar™? Instrument from its Wyatt Technology™? Portfolio for Nanoparticle Analysis

What Does Waters Corporation's (NYSE:WAT) Share Price Indicate?

Independent Director notifies of intention to sell stock

Waters Corporation Provides Earnings Guidance for the Third Quarter and Full Year 2023

Calculating The Intrinsic Value Of Waters Corporation (NYSE:WAT)

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Waters Corporation Launches XBridge Premier GTx BEH SEC Columns for Gene Therapy Applications

Waters Corporation: Temporary Headwinds Present A Buying Opportunity

These 4 Measures Indicate That Waters (NYSE:WAT) Is Using Debt Reasonably Well

Waters Corporation Boosts Resolution and Triples Scan Speed of Select Series MRT for Metabolomics and MS Imaging

Is Now The Time To Look At Buying Waters Corporation (NYSE:WAT)?

Price target decreased by 9.9% to US$311

Waters Corporation Provides Earnings Guidance for the Second Quarter of 2023 and Fiscal Year 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

A Look At The Intrinsic Value Of Waters Corporation (NYSE:WAT)

Here's Why Waters (NYSE:WAT) Can Manage Its Debt Responsibly

Independent Director recently bought US$998k worth of stock

What Is Waters Corporation's (NYSE:WAT) Share Price Doing?

Waters Corporation Provides Earnings Guidance for the First Quarter of 2023 and Fiscal Year 2023

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Waters Q4 2022 Earnings Preview

Waters Corp.: Now Best Price-Positioned Medical Services Stock

Waters Corporation (NYSE:WAT) Shares Could Be 31% Above Their Intrinsic Value Estimate

Waters Corporation Announces Waters_Connect™ System Monitoring

Does Waters (NYSE:WAT) Have A Healthy Balance Sheet?

Waters Corporation Announces Executive Changes